专利文献

专利


截止2016年年底,优卡迪共申请发明专利15项,其中肿瘤靶向嵌合抗原受体相关专利11项,免疫抑制联合嵌合抗原受体相关专利4项。
目前优卡迪有4个产品服务类商标正在申请中


最新文献


1. Tanoue K, Rosewell Shaw A, Watanabe N, Porter C, Rana B, et al. (2017) Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Res 77: 2040-2051.
2. (2017) CAR T-cell Therapy: Defining Response Characteristics. Cancer Discov.
3. Ormhoj M, Bedoya F, Frigault MJ, Maus MV (2017) CARs in the Lead Against Multiple Myeloma. Curr Hematol Malig Rep.
4. Hay KA, Turtle CJ (2017) Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies. Drugs 77: 237-245.
5. Makita S, Yoshimura K, Tobinai K (2017) Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Sci.
6. (2017) CRISPR Meets CAR T-cell Therapy. Cancer Discov.
7. Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, et al. (2017) CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep 7: 737.
8. Song Y, Tong C, Wang Y, Gao Y, Dai H, et al. (2017) Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo. Protein Cell.
9. Sommermeyer D, Hill T, Shamah SM, Salter AI, Chen Y, et al. (2017) Fully human CD19-specific chimeric antigen receptors for T-cell therapy. Leukemia. 
10. Gardner RA, Finney O, Annesley C, Brakke H, Summers C, et al. (2017) Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults. Blood.
11. Wang Z, Wu Z, Liu Y, Han W (2017) New development in CAR-T cell therapy. J Hematol Oncol 10: 53.
12. Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, et al. (2017) Optimized Depletion of Chimeric Antigen Receptor T-Cells in Murine Xenograft Models of Human Acute Myeloid Leukemia. Blood.
13. Lim WA, June CH (2017) The Principles of Engineering Immune Cells to Treat Cancer. Cell 168: 724-740.
14. Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, et al. (2017) Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543: 113-117.
15. (2017) Universal CAR T Cells Treat Leukemia. Cancer Discov 7: 342.